Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Legend Biotech to $78 from $72 and keeps an Overweight rating on the shares. The analyst named Legend a top pick for 2023. Carvykti is the best-in-class autologous BCMA CAR-T for relapsed/refractory multiple myeloma with demand far outpacing supply, Tenthoff tells investors in a research note. He now forecasts Carvykti sales of $129M this year, growing to $344M in 2023
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LEGN: